SETH LEDERMAN - 27 Feb 2024 Form 4/A Insider Report for Tonix Pharmaceuticals Holding Corp. (TNXP)

Role
Chief Executive Officer, Director
Signature
/s/ Seth Lederman
Issuer symbol
TNXP
Transactions as of
27 Feb 2024
Net transactions value
$0
Form type
4/A
Filing time
06 Mar 2024, 17:01:16 UTC
Date Of Original Report
29 Feb 2024
Previous filing
24 Feb 2023
Next filing
27 Feb 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TNXP Stock Option Award $0 +235,320 $0.000000 235,320 27 Feb 2024 Common Stock 235,320 $0.3680 Direct F1, F2
transaction TNXP Stock Option Award $0 +1,903,680 $0.000000 1,903,680 27 Feb 2024 Common Stock 1,903,680 $0.4600 Direct F1, F2
transaction TNXP Stock Option Award $0 +1,309,911 $0.000000 1,309,911 27 Feb 2024 Common Stock 1,309,911 $0.3680 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months.
F2 The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan.
F3 The amendment corrects the Conversion or Exercise Price of from $0.0368 to $0.368.